{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-032433","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.057334+00:00","generated_at":"2026-05-17T10:12:10.360619+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PDS Biotech reports mOS 39.3 months in VERSATILE-002 Phase 2 vs 17.9 months standard of care","bullets":["Median overall survival of 39.3 months (lower bound 23.9) in CPS≥1 patients with HPV16+ HNSCC; standard pembrolizumab ± chemo mOS is 17.9 months.","53 patients enrolled; no discontinuations due to treatment-related adverse events.","Phase 3 VERSATILE-003 trial is underway based on these results.","Durable multifunctional HPV16-specific CD8+ T cells induced by PDS0101 observed across demographics.","Full data set to be published later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-032433","json":"https://secwatch.observer/filing/0001140361-25-032433.json","markdown":"https://secwatch.observer/filing/0001140361-25-032433.md","text":"https://secwatch.observer/filing/0001140361-25-032433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125032433/0001140361-25-032433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125032433/ef20054394_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:12:10.360619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}